2016 CMHC Preliminary Program Agenda

Capital requirements are a given in any healthcare professional’s practice, but these are not skills taught in medical school education and thus, these decisions are often left to administrative employees who may or may not have the knowledge or understanding either. Attendees will leave this session better able to:

• Identify where to acquire capital
• Name asset acquisition basics: new equipment, new provider, new service line
• Explain capital budgeting: who gets what and why
• Discuss the good and bad aspects of debt

This activity has been approved for 1 AMA PRA Category 1 Credits™

Supported by educational funding from Tarsus Cardio Inc. dba Cardiometabolic Health Congress.

Good leadership skills are essential to build a successful practice. As a healthcare professional, how you lead impacts your ability as a provider and eventually, the quality, safety, and cost of the care you are giving your patients. But good leadership is a learned skill! Attendees will leave this session better able to:

• Identify and improve your leadership style so as to lead teams more effectively
• Discuss the right way HCPs can lead in order to create engagement of employees and patients
• Apply business fundamentals relating to private practice, hospital administration, and government agencies

This activity has been approved for 1 AMA PRA Category 1 Credits™

Supported by educational funding from Tarsus Cardio Inc. dba Cardiometabolic Health Congress.

One of the many challenges posed to clinicians today is that of the recognition, diagnosis and care of patients with rare diseases. The educational goals of this workshop are to raise clinician awareness about the prevalence of certain rare lipid disorders, and improve their diagnostic and therapeutic capabilities. Nationally recognized experts will discuss the prevalence of HoFH, LAL-D, FCS, and inherited forms of lipodystrophy, and the diagnostic and treatment challenges associated with them. Case studies will be presented to highlight the issues associated with these rare lipid disorders. A concluding panel discussion and audience question-and-answer session will reinforce key concepts and help clinicians understand how to effectively diagnose and manage rare lipid disorders to improve patient outcomes and reduce the risk of mortality when these disorders are undetected.

Learning Objectives

• Review the genetic epidemiology of rare lipid disorders
• Describe the pathophysiology associated with rare lipid disorders
• Identify characteristics of patients with rare lipid disorders
• Discuss the treatment challenges and novel/emerging therapies for rare lipid disorders

Supported in part by an educational grant from Alexion Pharmaceuticals, Inc. Endorsed by the FH Foundation.

Although it is well known that poor nutrition contributes to the development of most chronic conditions, including cardiovascular and metabolic diseases, many US medical schools still fail to adequately prepare future physicians for everyday nutrition challenges in clinical practice. In this symposium, Dr. Stephen Devries, Executive Director of the Gaples Institute for Integrative Cardiology, will provide an overview of diet for the primary prevention of conditions such as CVD and diabetes and discuss diet as adjunct for the treatment of established disease. Dr. Devries will also explain how to overcome obstacles to nutrition counseling in a busy practice, describe the use of rapid dietary assessment tools and utilization of motivational interviewing for nutritional goal setting, and provide strategies to implement one nutritional intervention at a time.

Learning Objectives

• Identify the magnitude of benefit possible from dietary interventions
• Discuss common nutrition questions with patients
• Apply motivational interviewing techniques to enhance patient engagement
• Explain how self-care among health professionals enhances lifestyle counseling

Supported by educational funding from Tarsus Cardio Inc. dba Cardiometabolic Health Congress.

This symposium is designed to update clinicians on the identification and diagnosis, as well as current guidelines and emerging algorithms for the treatment of statin intolerant patients. The efficacy and safety of current and emerging therapies for statin intolerant patients will also be reviewed during the symposium. Expert faculty will discuss the true incidence and diagnostic criteria of statin intolerance, the mechanistic rationale for lowering LDL-C through PCSK9 inhibition and other novel targets/pathways, treatment strategies, and where emerging therapies fit into current treatment guidelines and algorithms. Attendees will also have the opportunity to gain practical clinical perspective from an expert roundtable discussion on a statin intolerant patient case. This symposium is expected to improve lipid management of patients at increased ASCVD risk, particularly those with statin intolerance.

Learning Objectives

• Identify and diagnose patients with hypercholesterolemia who are statin intolerant based on symptoms, statin dose, past medical and family history, current list of medications, laboratory testing, genetic or acquired predisposition, and recommended definitions.
• Review recent lipid management guidelines and algorithms for effective management of statin intolerant patients requiring drug therapy for hypercholesterolemia.
• Evaluate the benefits versus risks of lipid-modifying drugs (including traditional and recently FDA approved) for the treatment of hypercholesterolemia in patients with elevated atherogenic cholesterol levels and statin intolerance based on safety and efficacy.
• List emerging lipid-modifying agents in development for the optimal treatment of statin intolerant patients.

Supported in part by educational funding donations provided by Amgen and Esperion Therapeutics, Inc.

This workshop will address the diagnosis and management of hyponatremia in HF patients by incorporating patient case examples into didactic presentations. Expert faculty will outline the major underlying causes of hyponatremia in HF patients, the 2013 EPR guidelines and differential algorithms for diagnosis, the safety and efficacy of current treatment options, and the complexities of HF to take into consideration when individualizing treatment. Multidisciplinary consultation will also be addressed to demonstrate the benefits of different perspectives in the diagnosis and treatment of these patients. Expert faculty will engage learners on these topics through a case-based format and stimulate practical clinical problem solving through a series of questions pertaining to the case. Finally, experts will provide clinicians with the ability to integrate diagnostic strategies into clinical practice and select treatment options for HF patients with hyponatremia in order to optimize patient outcomes.

Learning Objectives

• Identify the underlying causes of hyponatremia in patients with heart failure (HF) to appropriately manage the condition
• Interpret the 2013 EPR recommendations to diagnose hyponatremia in patients with HF
• Select treatment options for hyponatremia in patients with HF based on the efficacy and safety of available therapies and individual patient profile

Supported by an educational grant from Otsuka America Pharmaceutical Inc.

Despite well-established treatment guidelines, many patients with T2DM are not managed optimally and fail to achieve recommended levels of blood glucose control. Delays in initiating insulin, however, are common and may stem from both physician and patient barriers. Negative patient perceptions regarding insulin include complicated dosing regimens, fear of injections, and hypoglycemia. Clinician concerns include hypoglycemia, weight gain, and the misconception that elevated insulin increases cardiovascular risks.

This symposium will bring clinicians up to date on the latest available and emerging options in basal insulin therapy, alone and in combination with other antidiabetic agents. To help clinicians address the unmet needs of patients in this area, expert faculty will discuss common barriers to the initiation of and adherence to insulin therapy as well as strategies to overcome these barriers, including how to help patients successfully utilize new insulin delivery systems and technology designed to make therapy simpler and more convenient.

Learning Objectives

• Develop clinical strategies for the timely initiation and intensification of insulin therapy to achieve glycemic control
• List common patient barriers that limit the effectiveness of insulin-mediated glucose control and take steps to overcome them
• Discuss clinical outcomes data on new and emerging insulin formulations and combination insulin/incretin therapies, including pharmacological profiles surrounding efficacy and safety, such as effects on hypoglycemia and nocturnal hypoglycemia
• Integrate novel insulin therapies, combination therapies, and technologies into clinical practice to improve glucose control, reduce risk of weight gain and hypoglycemia, improve cardiovascular outcomes, and increase acceptance and adherence for patients

Supported by an educational grant from Novo Nordisk.

During this comprehensive learning experience, expert faculty will examine current lipid guidelines, the unmet need and residual risk of poorly controlled LDL-C, and exciting genetic insights that have expanded treatment targets. Attendees will leave with the latest information on novel LDL lowering therapies, including PCSK9 inhibitors. Clinical case examples will provide tactics for treatment intensification and how best to integrate new therapies into management plans for high-risk patients.

Learning Objectives

• Identify patient populations at high residual risk of CVD, despite statin therapy, particularly those with FH, ASCVD, or statin intolerance
• Assess the genetic basis and mechanistic rationale for lowering LDL-C through novel pathways, and the importance of LDL receptor recycling in cholesterol homeostasis.
• Review the latest clinical trial data and physiologic rationale for the new class, practicalities of administration, and patient selection.

Supported by an educational grant from Sanofi US and Regeneron Pharmaceuticals.

This educational activity is designed to update clinicians on the role of inflammation in the development and progression of atherosclerosis, the utilization of inflammatory biomarkers in assessing patients for secondary CVD risk, and the use of current and novel agents for the treatment of inflammation for secondary prevention of CVD risks. Expert faculty will engage in a roundtable discussion on these topics and present brief overviews on the pathogenesis of inflammation in atherosclerosis, the American College of Cardiology (ACC)/American Heart Association (AHA) 2013 guidelines and the National Lipid Association (NLA) Recommendations for the Patient-Centered Management of Dyslipidemia for the use of inflammatory biomarkers in patient assessment for secondary CVD risks, and evidence demonstrating the pleiotropic effects of statins and benefits and risks of current and novel agents for the treatment of inflammation in the prevention of secondary CVD risks. This symposium is expected to bring more focus to the role of inflammation in the initiation and progression of atherosclerosis and as a treatment target for patients at risk.

Learning Objectives

• Describe the role of inflammation in the pathogenesis of atherosclerosis
• Interpret the ACC/AHA 2013 guidelines and NLA recommendations for the use of inflammatory biomarkers to assess risk of secondary CV events
• Identify the benefits versus risks of statin therapy, including the anti-inflammatory properties of this drug class, for secondary prevention of CVD risks
• Recognize the efficacy and safety of current and emerging agents targeting inflammation for the secondary prevention of CVD risks

Supported by an educational grant from Novartis Pharmaceuticals Corporation.

This symposium will address clinical practice gaps and educational needs with didactic presentations and interactive case-based discussions regarding the updated 2014 AHA/ACC/HRS guideline recommendations for NVAF, the safety and efficacy of NOACs in patients with NVAF and comorbidities associated with metabolic syndrome, current and emerging reversal agents for NOACs, and recent regulations and processes for reimbursement designed to improve post-discharge adherence to anticoagulation/ antithrombotic treatment plans and reduce hospital readmissions.

Learning Objectives

• Identify individualized treatment regimens for patients with NVAF and comorbidities based on the 2014 AHA/ACC/HRS recommended evidence-based guidelines for the management of NVAF and safety and efficacy of OACs, particularly NOACs
• Describe reversal procedures and new and emerging reversal agents for OACs in NVAF patients with uncontrolled bleeding or who require emergency surgery
• Appraise the practical clinical aspects of NVAF management in order to reduce the incidence of hospital readmissions and improve the overall outcomes in patients with NVAF

Supported in part by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Management of patients who are at chronic risk for hyperkalemia frequently include dietary modifications and/or discontinuation of specific medications that confer renal and/or cardiac protection. Weighing the risk of hyperkalemia against the risk of discontinuing reno- and cardio-protective therapies can present a paradox to clinicians treating hyperkalemia. Although the short-term management of hyperkalemia can be very effective, the utility of current strategies to manage hyperkalemia is limited, with no long-term outcome data to guide in the management of this condition. New therapies to manage hyperkalemia are currently available and under development that may provide safer, more consistent management.

This symposium will review the most up-to-date clinical evidence on these new and potential therapies for the long-term management of hyperkalemia to improve guideline adherence and help clinicians move toward providing appropriate management for hyperkalemic patients with CKD, diabetes mellitus (DM), and/or HF by assessing risk profiles and customizing regimens based on individual patient needs.

Learning Objectives

• Evaluate unmet needs in the treatment of hyperkalemia based on treatment guidelines, practice patterns, and available therapies
• Discuss the benefits of novel agents that reduce risk of hyperkalemia in high-risk groups, such as CKD and HF
• Elaborate on new clinical trial data regarding timing of drug ingestion and safety issues with novel agents that reduce serum potassium levels
• Apply best practices for the treatment of hyperkalemia with potassium binding agents in patients with hyperkalemia based on clinical trial evidence and recent clinical experience

Supported by an educational grant from Relypsa, Inc.

This symposium will address knowledge and competency gaps surrounding HF prevention and management with a didactic presentation outlining the risk of HF in patients with cardiometabolic disease in order for HCPs to identify patients who may benefit from screening and if necessary the early initiation of HF treatment. Experts also explain the underlying genetic causes for racial disparities in HF and how biomarkers can assist physicians in predicting survival rates. Expert faculty will also review the 2013 ACCF/AHA guidelines to facilitate the appropriate use of guideline-directed pharmacotherapy recommendations in clinical practice. Additionally, this symposium will provide an overview of the different therapeutic classes of agents used to treat heart failure including recently approved therapies. To help clinicians differentiate and select among the various treatment options, patient cases will also be presented so that clinicians can gain experience selecting treatment regimens that optimize patient outcomes.

Learning Objectives

• Explain the importance of lifestyle modifications, including proper nutrition, in the prevention of heart failure (HF) and the need for screening in patients who may be at increased risk
• Describe the genetic variants that play a role in the increased risk of hypertension and HF in African American patients.
• Identify appropriate treatment regimens for patients with HF based on the presence of HF biomarkers and the ACC/AHA guideline recommendations.
• Evaluate the benefits versus risks of current and recently approved pharmacotherapies for HF based on efficacy and safety, and patient profiles

Supported by an educational grant from Arbor Pharmaceuticals, LLC and Metabolic Medical Institute.

Combining GLP-1RAs with basal insulin provides complementary action, lowering both PPG and FPG, to improve glycemic control in T2DM. The weight-sparing effect of GLP-1RAs makes them well suited for use in patients with concerns about insulin-induced weight gain. This symposium will discuss the use of insulin and GLP-1RA combinations to achieve glycemic control and potentially reduce cardiometabolic risk.

Learning Objectives

• Describe the clinical inertia that exists in T2DM as it relates to insulin therapy
• Summarize the clinical rationale and evidence for combining GLP-1 receptor agonists with basal insulin so as to address various underlying pathophysiologic components of type 2 diabetes
• Analyze the findings of recent clinical trials examining the use of basal insulin therapy in combination with GLP-1RAs for the management of patients with T2DM
• Compare the safety, efficacy, and pharmacological data on available and emerging basal insulin analogs in patients with diabetes
• Propose safe and effective treatment plans to achieve PPG control in patients who are not at goal using basal insulin

Supported by an educational grant from Sanofi-Aventis U.S.